Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
News|Articles|May 3, 2012
Skin Disorders Video 3: Boils
A boil, painful and nasty: Is it a cyst? Is it a bug bite? Should you culture? Is it MRSA? How should you treat it? What if it recurs? Listen and learn.
Advertisement
Ted Rosen, MD, Professor of Dermatology at Baylor College of Medicine, offers bite-size pieces of useful clinical information on the “Top 10” skin disorders you see in your daily practice.
Segment 3: Boils
For more webinar videos,
Advertisement
Related to this article
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Elevated PSA in Primary Care: What to Consider Before Biopsy
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
5